Hikal Secures Swissmedic GMP Certification for Bengaluru API Facility

Market snapshot: Hikal Limited announced that Swissmedic, the Swiss Agency for Therapeutic Products, has issued a Certificate of GMP Compliance for its active pharmaceutical ingredient facility in Jigani, Bengaluru. The accreditation confirms adherence to Good Manufacturing Practice standards recognized across European markets under mutual agreements.

Data Snapshot

• Swissmedic granted GMP certification for Hikal's active pharmaceutical ingredient facility located in Jigani, Bengaluru.
• The certification confirms compliance with European Union and Swiss Mutual Recognition Agreement standards.

Key Takeaways

• Swissmedic grants Good Manufacturing Practice compliance certification to Hikal's Bengaluru API facility.
• Certification aligns with the Mutual Recognition Agreement between Switzerland and the European Union, aiding EU market access.
• Builds on existing regulatory approvals from ANVISA (Brazil) and PMDA (Japan) for the same manufacturing location.

SAHI Perspective

The Swissmedic certification is a structural positive for Hikal's pharmaceutical division. By confirming GMP standards under the EU-Switzerland Mutual Recognition Agreement, Hikal reduces regulatory hurdles for European pharmaceutical clients, supporting higher-margin commercial scale-up.

Market Implications

Regulatory clearance at Jigani addresses compliance drag and strengthens commercial credibility with global pharmaceutical partners. This positioning allows Hikal to compete for active ingredient and contract development opportunities across Europe.

Trading Signals

Market Bias: Bullish

The Swissmedic approval establishes European GMP compliance for Hikal's Bengaluru facility, reinforcing customer confidence and market expansion potential across regulated jurisdictions.

Overweight: Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing (CDMO)

Trigger Factors:

• Commercial customer supply agreements in European markets
• Subsequent regulatory inspection outcomes by the US FDA or EDQM

Time Horizon: Near-term (0-3 months)

Industry Context

Regulated pharmaceutical markets require stringent cGMP compliance certified by stringent regulatory authorities. Approval under European-aligned authorities like Swissmedic enables API manufacturers to expand export footprints and contract development partnerships.

Key Risks to Watch

• Customer conversion timelines for European supply contracts
• Regulatory re-inspections or operational compliance maintenance costs

Recent Developments

In September 2026, Hikal commenced commercial production of Personal Care products at its multipurpose facility in Panoli, Gujarat, following shareholder approval of Sameer Hiremath as Chairman and Managing Director.

Closing Insight

Securing European-recognized GMP compliance strengthens Hikal's quality infrastructure, providing a foundation for active pharmaceutical ingredient order intake in highly regulated markets.

High Performance Trading with SAHI.